ASH Clinical News | Page 39

An investigational
technology from
Amgen

BiTE

®

Bispecific T cell Engager (BiTE®):
Engaging the immune system to
target malignant cells*

Cytotoxic T cells play an important role

T cell

Target cell

in the immune defense mechanism by identifying
and eliminating malignant target cells. T cells bind
to antigens on the surface of target cells, inducing
the release of cytotoxic components.1,2

However, malignant cells can evade

Malignant cell

T cell

destruction by cytotoxic T cells. Mechanisms
of evading the immune system can include
impaired antigen presentation, blockade of
T-cell receptor signaling, loss of regulatory
control of negative costimulatory signals,
and secretion of immunosuppressive factors.3

Novel Bispecific T cell Engager (BiTE®)

T cell

Malignant cell
BiTE

®

antibodies are designed to bridge T cells and target
cells with the goal of overcoming malignant cells’
evasion of the immune system.3,4 The clinical significance
of this is currently being investigated by Amgen.
* Proposed mechanism of BiTE ® function.

Learn more about BiTE® technology at www.BiTEAntibodies.com

© 2014 Amgen Inc. All rights reserved. 79963-R1-V3

Visit BiTEAntibodies.com

References: 1. Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. J Natl Cancer Inst. 2013;105:1172-1187. 2. Warrington R, Watson W, Kim HL, Antonetti FR. Allergy Asthma Clin Immunol. 2011;7(suppl 1):S1.
3. Rabinovich GA, Gabrilovich D, Sotomayer EM. Annu Rev Immunol. 2007;25:267-296. 4. Baeuerle PA, Reinhardt C. Cancer Res. 2009;69:4941-4944.